囊腫纖維化市場至2030年預測：按藥物類別、治療方法、給藥途徑、配銷通路和地區進行的全球分析

根據 Stratistics MRC 的資料，2023年全球囊腫纖維化市場規模為 114.9 億美元，預計在預測期內年複合成長率為 22.4%，到2030年將達到 473 億美元。

基因突變是導致囊腫纖維化（CF）遺傳疾病的原因。特定體液的蛋白質分泌受基因控制。這會影響身體的各個器官，並導致黏液和汗水變稠。此外，這種疾病會改變電解質輸送系統，導致細胞吸收鈉和水，進而導致負責分泌汗水和黏液的腺體出現問題。

根據囊腫纖維化患者登記處的資料，目前美國有超過 30,000 人患有這種疾病，估計全球約有 70,000 人患有這種疾病。

個人化醫療和基因檢測

基因序列測定技術和基因檢測的進步使得準確識別個別患者的 CFTR 基因突變成為可能。借助這種個體化方法，醫療專業人員可以根據每位患者的特定基因譜量身定做治療計劃並提供最合適的藥物。此外，對個人化醫療的重視可以提高病患滿意度和治療效果，進一步激發市場活力。

昂貴的醫療費用

囊腫纖維化的治療費用非常昂貴，尤其是 CFTR 調節劑，每年可達數十萬美元。此類過度支出可能會讓保險公司和衛生系統不堪重負，難以為所有患者提供服務。此外，對這些療法的長期負擔能力的擔憂也可能是由成本驅動的，影響市場擴張。

改善藥物傳輸系統

智慧型的進步改善治療管理。然而，這些實用且高效的給藥策略可確保患者獲得治療的全部益處，改善患者體驗，促進醫囑遵從性，最終有助於擴大市場。

複雜的治療計劃

囊腫纖維化治療計劃通常包括藥物、治療方法和生活方式改變之間的複雜相互作用。這種複雜性可能會讓患者不知所措並降低治療的醫囑遵從性。此外，違規可能會導致醫療費用增加和更頻繁的病情惡化。

COVID-19 的影響：

COVID-19大流行也對患者治療、臨床試驗和醫療保健系統造成重大干擾，影響了囊腫纖維化市場。這場大流行導致醫療資源緊張，減緩了新治療方法的推出，並推遲了研究和開發。被診斷出患有囊腫纖維化的人被認為是高風險族群，經常面臨更大的健康風險和獲得必要醫療照護的機會有限。此外，大流行的經濟影響增加了醫療保健系統和患者的經濟負擔，可能會影響囊腫纖維化治療的成本和可用性。

囊腫纖維化跨膜傳導調節劑調節劑部分預計在預測期內將是最大的

跨膜傳導調節劑調節劑預計將為這種複雜且具有挑戰性的遺傳疾病的治療帶來範式轉變，並且由於其變革性影響，預計將佔據囊腫纖維化市場的最大佔有率。此外，跨膜傳導調節劑（例如 Trikafta）已經改變了囊腫纖維化的治療方法。這些藥物透過解決導致囊腫纖維化的潛在遺傳缺陷來改善黏液清除和氯離子轉運。對於許多患有某些基因突變的患者來說，跨膜傳導調節劑可顯著改善肺功能，減少病情惡化，並改善生活品質。

預計吸入細分市場在預測期內年複合成長率最高

在囊腫纖維化市場中，吸入療法領域的年複合成長率最高。近年來，吸入療法變得越來越普及，因為它能夠以有針對性且有效的方式將藥物直接給藥到肺部。吸入器通常用於囊性纖維化治療，以輸送藥物來幫助控制囊腫纖維化的症狀。此外，吸入劑領域的顯著成長歸因於多種因素，例如吸入技術的進步、對吸入療法益處的認知不斷提高以及專門用於吸入給藥的新藥物的開發。

佔有率最大的地區

囊腫纖維化在北美擁有最大的市場佔有率。這是由於支持該地區市場主導地位的幾個因素。首先，在北美，無論是一般民眾或醫療相關人員對囊腫纖維化的認知度都很高，醫療基礎設施也很發達。這將有利於患者的早期診斷和治療，擴大患者基礎，並擴大囊腫纖維化治療藥物市場。此外，該地區擁有許多製藥公司和研究機構，積極致力於開發尖端的囊腫纖維化治療方法。最先進的醫療設備和優惠的醫療償付政策也推動了該地區的市場佔有率。

年複合成長率最高的地區：

預計亞太地區囊腫纖維化市場的年複合成長率最高。該地區囊腫纖維化患者的數量不斷增加，包括醫療保健在內的許多行業經歷快速成長。該地區的快速成長歸因於許多因素，包括公眾對囊腫纖維化的認知不斷提高、醫療基礎設施的改善以及醫療費用的上升。此外，中國和印度等政府實施目的是使醫療保健更加負擔得起和更容易獲得的計劃，提供更好的診斷和治療選擇，以幫助囊腫纖維化患者受益。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

• 公司簡介
  • 其他市場參與企業的綜合分析（最多 3 家公司）
  • 主要企業SWOT分析（最多3家企業）
• 區域細分
  • 根據客戶興趣對主要國家的市場估計/預測/年複合成長率（註：基於可行性檢查）
• 競爭基準化分析
  • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

• 概述
• 利害關係人
• 調查範圍
• 調查方法
  • 資料探勘
  • 資料分析
  • 資料檢驗
  • 研究途徑
• 調查來源
  • 主要調查來源
  • 二次調查來源
  • 先決條件

第3章 市場趨勢分析

• 介紹
• 促進因素
• 抑制因素
• 機會
• 威脅
• 新興市場
• 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

• 供應商的議價能力
• 買方議價能力
• 替代品的威脅
• 新進入者的威脅
• 競爭公司之間的敵對關係

第5章 全球囊腫纖維化市場：依藥物類別

• 介紹
• 胰酵素補充劑
• 黏液溶解劑
• 支氣管擴張劑
• 抗生素
• 囊腫纖維化跨膜傳導調節劑
• 其他藥物類別

第6章 全球囊腫纖維化市場：依治療方法

• 介紹
• 藥品
• 裝置

第7章 全球囊腫纖維化市場：依給藥途徑

• 介紹
• 口服
• 吸入

第8章 全球囊腫纖維化市場：依配銷通路

• 介紹
• 醫院
• 藥局
• 零售藥房
• 其他配銷通路

第9章 全球囊腫纖維化市場：依地區

• 介紹
• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲
  • 德國
  • 英國
  • 義大利
  • 法國
  • 西班牙
  • 歐洲其他地區
• 亞太地區
  • 日本
  • 中國
  • 印度
  • 澳洲
  • 紐西蘭
  • 韓國
  • 其他亞太地區
• 南美洲
  • 阿根廷
  • 巴西
  • 智利
  • 南美洲其他地區
• 中東和非洲
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 卡達
  • 南非
  • 中東和非洲其他地區

第10章 進展

• 合約、夥伴關係、協作和合資企業
• 收購和合併
• 新產品發布
• 業務擴展
• 其他關鍵策略

第11章 公司簡介

• Pharmaxis Ltd
• Gilead Sciences, Inc.
• Teva Pharmaceuticals
• Genentech Inc
• AbbVie Inc.
• Mylan NV
• Viatris Inc.
• Novartis AG
• Allergan PLC
• Pfizer Inc
• Nestle Health Science
• Hoffmann-La Roche AG
• BayerAG
• Vertex Pharmaceuticals Incorporated
• AstraZeneca
• Chiesi Farmaceutici SpA
• Horizon Therapeutic Plc.

According to Stratistics MRC, the Global Cystic Fibrosis Market is accounted for $11.49 billion in 2023 and is expected to reach $47.30 billion by 2030 growing at a CAGR of 22.4% during the forecast period. A genetic mutation is the cause of the inherited disease known as cystic fibrosis (CF). Certain bodily liquids' protein secretion is regulated by genes. This affects different organs in the body, which tends to thicken mucus and sweat. Moreover, this illness modifies the electrolyte transport system, which results in the absorption of sodium and water by cells and causes issues with the glands responsible for producing sweat and mucus.

According to the Cystic Fibrosis Patient Registry, it is estimated that more than 30,000 people are currently suffering from this condition in the U.S. and it is estimated that about 70,000 people are suffering from it across the globe.

Market Dynamics:

Driver:

Personalized medicine and genetic testing

The ability to precisely identify CFTR gene mutations in individual patients has been made possible by advances in genetic sequencing technologies and genetic testing. With the help of this individualized approach, medical professionals can customize treatment plans and offer the best medications depending on each patient's particular genetic profile. Additionally, the market is further propelled by the emphasis on personalized medicine, which raises patient satisfaction and treatment effectiveness.

Restraint:

Expensive medical care

The cost of treating cystic fibrosis can be extremely high, sometimes amounting to hundreds of thousands of dollars per year, particularly for CFTR modulators. These excessive expenses may put pressure on insurers and healthcare systems, making it more difficult to provide access to all patients. Furthermore, concerns about these treatments' long-term affordability are also brought up by cost, which could have an impact on market expansion.

Opportunity:

Improvements in medication delivery systems

Treatment administration has been enhanced by advances in drug delivery, such as intelligent inhalers and effective nebulizers. However, since they guarantee that patients get the full benefit of their treatments, these practical and efficient drug delivery strategies improve patient experience, promote adherence, and subsequently aid in market expansion.

Threat:

Complex therapy plans

Treatment plans for cystic fibrosis frequently entail a complicated mix of drugs, therapies, and lifestyle modifications. This complexity has the potential to overwhelm patients and result in poor adherence to treatment, which will ultimately compromise the efficacy of therapies and patient outcomes. Moreover, healthcare expenses may rise, and exacerbations may occur more frequently as a result of noncompliance.

COVID-19 Impact:

The COVID-19 pandemic caused major disruptions in patient care, clinical trials, and healthcare systems, which in turn affected the cystic fibrosis market. The pandemic put a strain on healthcare resources, delayed the introduction of new treatments, and postponed research and development. Individuals diagnosed with cystic fibrosis, who were regarded as a high-risk population, experienced increased health risks and frequently had limited access to necessary medical care. Furthermore, the pandemic's economic effects put more strain on healthcare systems and patients' finances, which might have an impact on the cost and accessibility of cystic fibrosis treatments.

The Cystic Fibrosis Transmembrane Conductance Regulator Modulators segment is expected to be the largest during the forecast period

CFTR modulators are expected to hold the largest share in the cystic fibrosis market due to their transformative impact, which is expected to represent a paradigm shift in the treatment of this complex and challenging genetic disease. Moreover, treatment for cystic fibrosis has been transformed by CFTR modulators such as Trikafta. These medications improve mucus clearance and chloride transport by addressing the underlying genetic defect that causes cystic fibrosis. For many patients with particular genetic mutations, CFTR modulators greatly improve lung function, lower exacerbations, and improve quality of life.

The Inhaled segment is expected to have the highest CAGR during the forecast period

The inhaled segment of the cystic fibrosis market has the highest CAGR. Because inhaled therapies deliver medication directly to the lungs in a targeted and effective manner, they have become increasingly popular in recent years. Inhalers are commonly used in these therapies to deliver medications that assist in controlling the symptoms of cystic fibrosis. Additionally, the significant growth of the inhaled segment can be attributed to various factors, such as the progression of inhalation technology, heightened consciousness regarding the advantages of inhalation treatments, and the creation of novel medications especially intended for inhalation administration.

Region with largest share:

North America holds the largest market share for cystic fibrosis. This is explained by a number of factors that support the region's market dominance. First off, both the general public and medical professionals in North America are highly aware of cystic fibrosis, and the continent has a well-established healthcare infrastructure. This makes it easier to diagnose and treat patients early, which expands the patient pool and raises the market for cystic fibrosis treatments. Furthermore, there are many pharmaceutical companies and research facilities in the area that are actively working to develop cutting-edge cystic fibrosis treatments. The availability of cutting-edge medical equipment and advantageous reimbursement practices also boost the market share of the area.

Region with highest CAGR:

The Asia-Pacific region is anticipated to have the highest CAGR in the cystic fibrosis market. This region is seeing a rise in the number of cases of cystic fibrosis and is seeing rapid growth in a number of industries, including healthcare. The region's rapid growth is attributed to a number of factors, including expanding public awareness of cystic fibrosis, enhancing healthcare infrastructure, and rising healthcare costs. Moreover, governments in nations such as China and India are implementing programs aimed at improving healthcare affordability and accessibility, which will benefit patients with cystic fibrosis by providing better options for diagnosis and treatment.

Key players in the market

Some of the key players in Cystic Fibrosis market include: Pharmaxis Ltd , Gilead Sciences, Inc., Teva Pharmaceuticals, Genentech Inc , AbbVie Inc., Mylan N.V, Viatris Inc., Novartis AG, Allergan PLC, Pfizer Inc, Nestle Health Science, Hoffmann-La Roche AG , BayerAG, Vertex Pharmaceuticals Incorporated, AstraZeneca , Chiesi Farmaceutici SpA and Horizon Therapeutic Plc.

Key Developments:

In October 2023, Teva Pharmaceuticals and Sanofi have announced an agreement to jointly develop and commercialise a treatment for inflammatory bowel disease, with the deal potentially worth up to $1.5bn.The candidate, Teva's TEV'574, is an anti-TL1A therapy currently being evaluated in phase 2b clinical trials as a treatment for ulcerative colitis and Crohn's disease, the two main types of inflammatory bowel disease.

In October 2023, Viatris Inc., a global healthcare company, today announced it has received an offer for the divestiture of substantially all of its Over-the-Counter (OTC) business, and has entered into definitive agreements to divest its Women's Healthcare business, its Active Pharmaceutical Ingredients (API) business in India and commercialization rights in certain non-core markets that were acquired as part of the Upjohn Transaction.

In September 2023, PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical today announced a new multi-target collaboration and license agreement with U.S.-based Genentech, a member of the Roche Group, focused on the discovery and development of novel macrocyclic peptide-radioisotope ("peptide-RI") drug conjugates.

Drug Classes Covered:

• Pancreatic Enzyme Supplements
• Mucolytic
• Bronchodilators
• Antibiotics
• Cystic Fibrosis Transmembrane Conductance Regulator Modulators
• Other Drug Classes

Treatment Methods Covered:

• Medication
• Devices

Route of Administrations Covered:

• Oral
• Inhaled

Distribution Channels Covered:

• Hospital
• Drug Stores
• Retail Pharmacies
• Other Distribution Channels

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Emerging Markets
• 3.7 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Cystic Fibrosis Market, By Drug Class

• 5.1 Introduction
• 5.2 Pancreatic Enzyme Supplements
• 5.3 Mucolytic
• 5.4 Bronchodilators
• 5.5 Antibiotics
• 5.6 Cystic Fibrosis Transmembrane Conductance Regulator Modulators
• 5.7 Other Drug Classes

6 Global Cystic Fibrosis Market, By Treatment Method

• 6.1 Introduction
• 6.2 Medication
• 6.3 Devices

7 Global Cystic Fibrosis Market, By Route of Administration

• 7.1 Introduction
• 7.2 Oral
• 7.3 Inhaled

8 Global Cystic Fibrosis Market, By Distribution Channel

• 8.1 Introduction
• 8.2 Hospital
• 8.3 Drug Stores
• 8.4 Retail Pharmacies
• 8.5 Other Distribution Channels

9 Global Cystic Fibrosis Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Pharmaxis Ltd
• 11.2 Gilead Sciences, Inc.
• 11.3 Teva Pharmaceuticals
• 11.4 Genentech Inc
• 11.5 AbbVie Inc.
• 11.6 Mylan N.V
• 11.7 Viatris Inc.
• 11.8 Novartis AG
• 11.9 Allergan PLC
• 11.10 Pfizer Inc
• 11.11 Nestle Health Science
• 11.12 Hoffmann-La Roche AG
• 11.13 BayerAG
• 11.14 Vertex Pharmaceuticals Incorporated
• 11.15 AstraZeneca
• 11.16 Chiesi Farmaceutici SpA
• 11.17 Horizon Therapeutic Plc.

List of Tables

• Table 1 Global Cystic Fibrosis Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Cystic Fibrosis Market Outlook, By Drug Class (2021-2030) ($MN)
• Table 3 Global Cystic Fibrosis Market Outlook, By Pancreatic Enzyme Supplements (2021-2030) ($MN)
• Table 4 Global Cystic Fibrosis Market Outlook, By Mucolytic (2021-2030) ($MN)
• Table 5 Global Cystic Fibrosis Market Outlook, By Bronchodilators (2021-2030) ($MN)
• Table 6 Global Cystic Fibrosis Market Outlook, By Antibiotics (2021-2030) ($MN)
• Table 7 Global Cystic Fibrosis Market Outlook, By Cystic Fibrosis Transmembrane Conductance Regulator Modulators (2021-2030) ($MN)
• Table 8 Global Cystic Fibrosis Market Outlook, By Other Drug Classes (2021-2030) ($MN)
• Table 9 Global Cystic Fibrosis Market Outlook, By Treatment Method (2021-2030) ($MN)
• Table 10 Global Cystic Fibrosis Market Outlook, By Medication (2021-2030) ($MN)
• Table 11 Global Cystic Fibrosis Market Outlook, By Devices (2021-2030) ($MN)
• Table 12 Global Cystic Fibrosis Market Outlook, By Route of Administration (2021-2030) ($MN)
• Table 13 Global Cystic Fibrosis Market Outlook, By Oral (2021-2030) ($MN)
• Table 14 Global Cystic Fibrosis Market Outlook, By Inhaled (2021-2030) ($MN)
• Table 15 Global Cystic Fibrosis Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 16 Global Cystic Fibrosis Market Outlook, By Hospital (2021-2030) ($MN)
• Table 17 Global Cystic Fibrosis Market Outlook, By Drug Stores (2021-2030) ($MN)
• Table 18 Global Cystic Fibrosis Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 19 Global Cystic Fibrosis Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
• Table 20 North America Cystic Fibrosis Market Outlook, By Country (2021-2030) ($MN)
• Table 21 North America Cystic Fibrosis Market Outlook, By Drug Class (2021-2030) ($MN)
• Table 22 North America Cystic Fibrosis Market Outlook, By Pancreatic Enzyme Supplements (2021-2030) ($MN)
• Table 23 North America Cystic Fibrosis Market Outlook, By Mucolytic (2021-2030) ($MN)
• Table 24 North America Cystic Fibrosis Market Outlook, By Bronchodilators (2021-2030) ($MN)
• Table 25 North America Cystic Fibrosis Market Outlook, By Antibiotics (2021-2030) ($MN)
• Table 26 North America Cystic Fibrosis Market Outlook, By Cystic Fibrosis Transmembrane Conductance Regulator Modulators (2021-2030) ($MN)
• Table 27 North America Cystic Fibrosis Market Outlook, By Other Drug Classes (2021-2030) ($MN)
• Table 28 North America Cystic Fibrosis Market Outlook, By Treatment Method (2021-2030) ($MN)
• Table 29 North America Cystic Fibrosis Market Outlook, By Medication (2021-2030) ($MN)
• Table 30 North America Cystic Fibrosis Market Outlook, By Devices (2021-2030) ($MN)
• Table 31 North America Cystic Fibrosis Market Outlook, By Route of Administration (2021-2030) ($MN)
• Table 32 North America Cystic Fibrosis Market Outlook, By Oral (2021-2030) ($MN)
• Table 33 North America Cystic Fibrosis Market Outlook, By Inhaled (2021-2030) ($MN)
• Table 34 North America Cystic Fibrosis Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 35 North America Cystic Fibrosis Market Outlook, By Hospital (2021-2030) ($MN)
• Table 36 North America Cystic Fibrosis Market Outlook, By Drug Stores (2021-2030) ($MN)
• Table 37 North America Cystic Fibrosis Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 38 North America Cystic Fibrosis Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
• Table 39 Europe Cystic Fibrosis Market Outlook, By Country (2021-2030) ($MN)
• Table 40 Europe Cystic Fibrosis Market Outlook, By Drug Class (2021-2030) ($MN)
• Table 41 Europe Cystic Fibrosis Market Outlook, By Pancreatic Enzyme Supplements (2021-2030) ($MN)
• Table 42 Europe Cystic Fibrosis Market Outlook, By Mucolytic (2021-2030) ($MN)
• Table 43 Europe Cystic Fibrosis Market Outlook, By Bronchodilators (2021-2030) ($MN)
• Table 44 Europe Cystic Fibrosis Market Outlook, By Antibiotics (2021-2030) ($MN)
• Table 45 Europe Cystic Fibrosis Market Outlook, By Cystic Fibrosis Transmembrane Conductance Regulator Modulators (2021-2030) ($MN)
• Table 46 Europe Cystic Fibrosis Market Outlook, By Other Drug Classes (2021-2030) ($MN)
• Table 47 Europe Cystic Fibrosis Market Outlook, By Treatment Method (2021-2030) ($MN)
• Table 48 Europe Cystic Fibrosis Market Outlook, By Medication (2021-2030) ($MN)
• Table 49 Europe Cystic Fibrosis Market Outlook, By Devices (2021-2030) ($MN)
• Table 50 Europe Cystic Fibrosis Market Outlook, By Route of Administration (2021-2030) ($MN)
• Table 51 Europe Cystic Fibrosis Market Outlook, By Oral (2021-2030) ($MN)
• Table 52 Europe Cystic Fibrosis Market Outlook, By Inhaled (2021-2030) ($MN)
• Table 53 Europe Cystic Fibrosis Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 54 Europe Cystic Fibrosis Market Outlook, By Hospital (2021-2030) ($MN)
• Table 55 Europe Cystic Fibrosis Market Outlook, By Drug Stores (2021-2030) ($MN)
• Table 56 Europe Cystic Fibrosis Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 57 Europe Cystic Fibrosis Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
• Table 58 Asia Pacific Cystic Fibrosis Market Outlook, By Country (2021-2030) ($MN)
• Table 59 Asia Pacific Cystic Fibrosis Market Outlook, By Drug Class (2021-2030) ($MN)
• Table 60 Asia Pacific Cystic Fibrosis Market Outlook, By Pancreatic Enzyme Supplements (2021-2030) ($MN)
• Table 61 Asia Pacific Cystic Fibrosis Market Outlook, By Mucolytic (2021-2030) ($MN)
• Table 62 Asia Pacific Cystic Fibrosis Market Outlook, By Bronchodilators (2021-2030) ($MN)
• Table 63 Asia Pacific Cystic Fibrosis Market Outlook, By Antibiotics (2021-2030) ($MN)
• Table 64 Asia Pacific Cystic Fibrosis Market Outlook, By Cystic Fibrosis Transmembrane Conductance Regulator Modulators (2021-2030) ($MN)
• Table 65 Asia Pacific Cystic Fibrosis Market Outlook, By Other Drug Classes (2021-2030) ($MN)
• Table 66 Asia Pacific Cystic Fibrosis Market Outlook, By Treatment Method (2021-2030) ($MN)
• Table 67 Asia Pacific Cystic Fibrosis Market Outlook, By Medication (2021-2030) ($MN)
• Table 68 Asia Pacific Cystic Fibrosis Market Outlook, By Devices (2021-2030) ($MN)
• Table 69 Asia Pacific Cystic Fibrosis Market Outlook, By Route of Administration (2021-2030) ($MN)
• Table 70 Asia Pacific Cystic Fibrosis Market Outlook, By Oral (2021-2030) ($MN)
• Table 71 Asia Pacific Cystic Fibrosis Market Outlook, By Inhaled (2021-2030) ($MN)
• Table 72 Asia Pacific Cystic Fibrosis Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 73 Asia Pacific Cystic Fibrosis Market Outlook, By Hospital (2021-2030) ($MN)
• Table 74 Asia Pacific Cystic Fibrosis Market Outlook, By Drug Stores (2021-2030) ($MN)
• Table 75 Asia Pacific Cystic Fibrosis Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 76 Asia Pacific Cystic Fibrosis Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
• Table 77 South America Cystic Fibrosis Market Outlook, By Country (2021-2030) ($MN)
• Table 78 South America Cystic Fibrosis Market Outlook, By Drug Class (2021-2030) ($MN)
• Table 79 South America Cystic Fibrosis Market Outlook, By Pancreatic Enzyme Supplements (2021-2030) ($MN)
• Table 80 South America Cystic Fibrosis Market Outlook, By Mucolytic (2021-2030) ($MN)
• Table 81 South America Cystic Fibrosis Market Outlook, By Bronchodilators (2021-2030) ($MN)
• Table 82 South America Cystic Fibrosis Market Outlook, By Antibiotics (2021-2030) ($MN)
• Table 83 South America Cystic Fibrosis Market Outlook, By Cystic Fibrosis Transmembrane Conductance Regulator Modulators (2021-2030) ($MN)
• Table 84 South America Cystic Fibrosis Market Outlook, By Other Drug Classes (2021-2030) ($MN)
• Table 85 South America Cystic Fibrosis Market Outlook, By Treatment Method (2021-2030) ($MN)
• Table 86 South America Cystic Fibrosis Market Outlook, By Medication (2021-2030) ($MN)
• Table 87 South America Cystic Fibrosis Market Outlook, By Devices (2021-2030) ($MN)
• Table 88 South America Cystic Fibrosis Market Outlook, By Route of Administration (2021-2030) ($MN)
• Table 89 South America Cystic Fibrosis Market Outlook, By Oral (2021-2030) ($MN)
• Table 90 South America Cystic Fibrosis Market Outlook, By Inhaled (2021-2030) ($MN)
• Table 91 South America Cystic Fibrosis Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 92 South America Cystic Fibrosis Market Outlook, By Hospital (2021-2030) ($MN)
• Table 93 South America Cystic Fibrosis Market Outlook, By Drug Stores (2021-2030) ($MN)
• Table 94 South America Cystic Fibrosis Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 95 South America Cystic Fibrosis Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
• Table 96 Middle East & Africa Cystic Fibrosis Market Outlook, By Country (2021-2030) ($MN)
• Table 97 Middle East & Africa Cystic Fibrosis Market Outlook, By Drug Class (2021-2030) ($MN)
• Table 98 Middle East & Africa Cystic Fibrosis Market Outlook, By Pancreatic Enzyme Supplements (2021-2030) ($MN)
• Table 99 Middle East & Africa Cystic Fibrosis Market Outlook, By Mucolytic (2021-2030) ($MN)
• Table 100 Middle East & Africa Cystic Fibrosis Market Outlook, By Bronchodilators (2021-2030) ($MN)
• Table 101 Middle East & Africa Cystic Fibrosis Market Outlook, By Antibiotics (2021-2030) ($MN)
• Table 102 Middle East & Africa Cystic Fibrosis Market Outlook, By Cystic Fibrosis Transmembrane Conductance Regulator Modulators (2021-2030) ($MN)
• Table 103 Middle East & Africa Cystic Fibrosis Market Outlook, By Other Drug Classes (2021-2030) ($MN)
• Table 104 Middle East & Africa Cystic Fibrosis Market Outlook, By Treatment Method (2021-2030) ($MN)
• Table 105 Middle East & Africa Cystic Fibrosis Market Outlook, By Medication (2021-2030) ($MN)
• Table 106 Middle East & Africa Cystic Fibrosis Market Outlook, By Devices (2021-2030) ($MN)
• Table 107 Middle East & Africa Cystic Fibrosis Market Outlook, By Route of Administration (2021-2030) ($MN)
• Table 108 Middle East & Africa Cystic Fibrosis Market Outlook, By Oral (2021-2030) ($MN)
• Table 109 Middle East & Africa Cystic Fibrosis Market Outlook, By Inhaled (2021-2030) ($MN)
• Table 110 Middle East & Africa Cystic Fibrosis Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 111 Middle East & Africa Cystic Fibrosis Market Outlook, By Hospital (2021-2030) ($MN)
• Table 112 Middle East & Africa Cystic Fibrosis Market Outlook, By Drug Stores (2021-2030) ($MN)
• Table 113 Middle East & Africa Cystic Fibrosis Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 114 Middle East & Africa Cystic Fibrosis Market Outlook, By Other Distribution Channels (2021-2030) ($MN)